NextCure, Inc. (NXTC) has a negative trailing P/E of -0.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -143.90%.
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -29.2 | 0.00 | -18.52 | 0.00 | - |
| 2018 | -19.8 | -0.42 | -9.63 | 0.00 | - |
| 2019 | -26.2 | -0.23 | 2.75 | 139.30 | - |
| 2020 | -8.2 | 0.21 | 1.02 | 13.41 | - |
| 2021 | -2.4 | -0.03 | 0.71 | 0.00 | - |
| 2022 | -0.5 | -0.07 | 0.23 | 0.00 | - |
| 2023 | -0.5 | 0.03 | 0.28 | 0.00 | - |
| 2024 | -0.4 | 0.03 | 0.33 | 0.00 | - |
| 2025 | -0.7 | 0.04 | 1.15 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-1.54 | $0.00 | $-15.47M | - |
| 2018 | $-2.27 | $0.00 | $-22.8M | - |
| 2019 | $-2.15 | $6.35M | $-33.74M | -531.5% |
| 2020 | $-1.21 | $22.38M | $-33.19M | -148.3% |
| 2021 | $-2.51 | $0.00 | $-69.39M | - |
| 2022 | $-2.50 | $0.00 | $-69.43M | - |
| 2023 | $-2.25 | $0.00 | $-62.72M | - |
| 2024 | $-1.99 | $0.00 | $-55.65M | - |
| 2025 | $-19.65 | $0.00 | $-55.84M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-7.91 | $-8.48 – $-7.39 | $3.3M | $3.3M – $3.3M | 3 |
| 2027 | $-9.15 | $-13.27 – $-5.03 | $7M | $7M – $7M | 2 |
| 2028 | $-3.34 | $-3.34 – $-3.34 | $10.3M | $10.3M – $10.3M | 1 |
| 2029 | $-2.29 | $-2.29 – $-2.29 | $22.6M | $22.6M – $22.6M | 1 |
| 2030 | $-0.22 | $-0.22 – $-0.22 | $39.7M | $39.7M – $39.7M | 1 |
